Study shows new obesity treatment semaglutide causes similar weight loss across different age groups

The STEP trials published over the past year have established the efficacy and safety of semaglutide in treating patients with obesity. A new study analysing the effects of this treatment in different age groups presented at this year’s European Congress on Obesity (held online, 10-13 May), shows that it has similar effectiveness across different age groups with regard to weight loss (under 40 years, 40-60 years, and 60 years and over).

Share:

Facebook
Twitter
Pinterest
LinkedIn

Leave a Reply

Related Posts

Vitamins and Minerals

Vitamins and minerals are micronutrients required by the body to carry out a range of normal functions. However, these micronutrients are not produced in our